medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2022, Number 3

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2022; 38 (3)

Treatment of idiopathic pulmonary fibrosis with autologous adult bone marrow stem cells

Tello VS

Language: Spanish
References: 13
Page: 1-8
PDF size: 436.67 Kb.


ABSTRACT

Introduction: Idiopathic pulmonary fibrosis represents a degenerative disease with a dire prognosis, whose therapeutic options are very limited, so it is necessary to evaluate alternatives available to the population.
Objective: To evaluate treatment with autologous adult bone marrow (BM) stem cells in a 68-year-old patient with a radiological diagnosis of pulmonary fibrosis and dyspnea at rest.
Case presentation: The patient attended the consultation with dyspnea at rest, and digital saturation of 74%, which after her first intravenous treatment with adult bone marrow stem cells, achieved significant improvement, with saturations ranging between 85 and 90% at 4 months after the first therapy. Eight months after the first session, she received a second dose, with which she increased the saturation to values between 94 and 97%, three weeks after the latter.
Conclusion: Conclusion: Treatment with autologous adult bone marrow stem cells could improve the signs and symptoms of patients with idiopathic pulmonary fibrosis.


REFERENCES

  1. Kamiya H, Panlaqui OM. Systematic review and meta-analysis of prognostic factors of acute exacerbation of idiopathic pulmonary fibrosis. BMJ Open. 2020 Jun 15;10(6):e035420. DOI: https://10.1136/bmjopen-2019-0354201.

  2. Akram KM, Patel N, Spiteri MA, Forsyth NR. Lung Regeneration: Endogenous and Exogenous Stem Cell Mediated Therapeutic Approaches. Int J Mol Sci. 2016;17(1):128. DOI: https://10.3390/ijms170101282.

  3. Antoniou KM, Papadaki HA, Soufla G, Kastrinaki MC, Damianaki A, Koutala H, et al. Investigation of bone marrow mesenchymal stem cells (BM MSCs) involvement in idiopathic pulmonary fibrosis (IPF). Respir Med. 2010;104(10):1535-42. DOI: https://10.1016/j.rmed.2010.04.0153.

  4. Gazdhar A, Susuri N, Hostettler K, Gugger M, Knudsen L, Roth M, et al. HGF Expressing Stem Cells in Usual Interstitial Pneumonia Originate from the Bone Marrow and Are Antifibrotic. PLoS One. 2013;8(6):e65453. DOI: https://10.1371/journal.pone.00654534.

  5. Zhao Y, Yan Z, Liu Y, Zhang Y, Shi J, Li J, et al. Effectivity of mesenchymal stem cells for bleomycin-induced pulmonary fibrosis: a systematic review and implication for clinical application. Stem Cell Res Ther. 2021 Aug 23;12(1):470. DOI: https://10.1186/s13287-021-02551-y5.

  6. Li X, Yue S, Luo Z. Mesenchymal stem cells in idiopathic pulmonary fibrosis. Oncotarget. 2017 May 23;8(60):102600-16. DOI: https://10.18632/oncotarget.181266.

  7. Tzouvelekis A, Toonkel R, Karampitsakos T, Medapalli K, Ninou I, Aidinis V, et al. Mesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis. Front Med (Lausanne). 2018;5:142. DOI: https://10.3389/fmed.2018.001427.

  8. Ntolios P, Steiropoulos P, Karpathiou G, Anevlavis S, Karampitsakos T, Bouros E, et al. Cell Therapy for Idiopathic Pulmonary Fibrosis: Rationale and Progress to Date. BioDrugs. 2020;34(5):543-556. DOI: https://10.1007/s40259-020-00437-88.

  9. Kamiya H, Panlaqui OM. Systematic review and meta-analysis of clinical significance of autoantibodies for idiopathic pulmonary fibrosis. BMJ Open. 2019;9(5):e027849. DOI: https://10.1136/bmjopen-2018-0278499.

  10. Ali KM, Fattah FHR, Omar SH, Gubari MIM, Yousefifard M, Hosseini M. Mesenchymal Stromal Cells Derived Conditioned Medium in Pulmonary Fibrosis: A Systematic Review and Meta-analysis. Arch Iran Med. 2020;23(12):870-9. DOI: https://10.34172/aim.2020.11610.

  11. Bateman ME, Strong AL, Gimble JM, Bunnell BA. Concise Review: Using Fat to Fight Disease: A Systematic Review of Nonhomologous Adipose-Derived Stromal/Stem Cell Therapies. Stem Cells. 2018;36(9):1311-28 DOI: https://10.1002/stem.284711.

  12. Hostettler KE, Gazdhar A, Khan P, Savic S, Tamo L, Lardinois D, et al. Multipotent mesenchymal stem cells in lung fibrosis. PLoS One. 2017;12(8):e0181946. DOI: https://10.1371/journal.pone.018194612.

  13. Bonifazi M, Di Vincenzo M, Caffarini M, Mei F, Salati M, Zuccatosta L, et al. How the Pathological Microenvironment Affects the Behavior of Mesenchymal Stem Cells in the Idiopathic Pulmonary Fibrosis. Int J Mol Sci. 2020;21(21):8140. DOI: https://10.3390/ijms2121814013.




2020     |     www.medigraphic.com